|

C7R.CD30.CAR-EBVST cells Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Allogeneic CR7.CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes

Pipeline

Phase 1: 1

Top Sponsors

  • Baylor College of Medicine1

Indications

  • Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type1
  • CD30-Positive Diffuse Large B-Cell Lymphoma1
  • Anaplastic Large Cell Lymphoma, ALK-negative1
  • Anaplastic Large Cell Lymphoma, ALK-Positive1
  • Peripheral T Cell Lymphoma1

Houston, Texas1 trial

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Houston Methodist Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.